Enhancing the Capabilities of Continuous Glucose Monitoring With a Predictive App.

IF 4.1 Q2 ENDOCRINOLOGY & METABOLISM
Pau Herrero, Magí Andorrà, Nils Babion, Hendericus Bos, Matthias Koehler, Yannick Klopfenstein, Eemeli Leppäaho, Patrick Lustenberger, Ajandek Peak, Christian Ringemann, Timor Glatzer
{"title":"Enhancing the Capabilities of Continuous Glucose Monitoring With a Predictive App.","authors":"Pau Herrero, Magí Andorrà, Nils Babion, Hendericus Bos, Matthias Koehler, Yannick Klopfenstein, Eemeli Leppäaho, Patrick Lustenberger, Ajandek Peak, Christian Ringemann, Timor Glatzer","doi":"10.1177/19322968241267818","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite abundant evidence demonstrating the benefits of continuous glucose monitoring (CGM) in diabetes management, a significant proportion of people using this technology still struggle to achieve glycemic targets. To address this challenge, we propose the Accu-Chek<sup>®</sup> SmartGuide Predict app, an innovative CGM digital companion that incorporates a suite of advanced glucose predictive functionalities aiming to inform users earlier about acute glycemic situations.</p><p><strong>Methods: </strong>The app's functionalities, powered by three machine learning models, include a two-hour glucose forecast, a 30-minute low glucose detection, and a nighttime low glucose prediction for bedtime interventions. Evaluation of the models' performance included three data sets, comprising subjects with T1D on MDI (n = 21), subjects with type 2 diabetes (T2D) on MDI (n = 59), and subjects with T1D on insulin pump therapy (n = 226).</p><p><strong>Results: </strong>On an aggregated data set, the two-hour glucose prediction model, at a forecasting horizon of 30, 45, 60, and 120 minutes, achieved a percentage of data points in zones A and B of Consensus Error Grid of: 99.8%, 99.3%, 98.7%, and 96.3%, respectively. The 30-minute low glucose prediction model achieved an accuracy, sensitivity, specificity, mean lead time, and area under the receiver operating characteristic curve (ROC AUC) of: 98.9%, 95.2%, 98.9%, 16.2 minutes, and 0.958, respectively. The nighttime low glucose prediction model achieved an accuracy, sensitivity, specificity, and ROC AUC of: 86.5%, 55.3%, 91.6%, and 0.859, respectively.</p><p><strong>Conclusions: </strong>The consistency of the performance of the three predictive models when evaluated on different cohorts of subjects with T1D and T2D on different insulin therapies, including real-world data, offers reassurance for real-world efficacy.</p>","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":null,"pages":null},"PeriodicalIF":4.1000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418465/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/19322968241267818","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Despite abundant evidence demonstrating the benefits of continuous glucose monitoring (CGM) in diabetes management, a significant proportion of people using this technology still struggle to achieve glycemic targets. To address this challenge, we propose the Accu-Chek® SmartGuide Predict app, an innovative CGM digital companion that incorporates a suite of advanced glucose predictive functionalities aiming to inform users earlier about acute glycemic situations.

Methods: The app's functionalities, powered by three machine learning models, include a two-hour glucose forecast, a 30-minute low glucose detection, and a nighttime low glucose prediction for bedtime interventions. Evaluation of the models' performance included three data sets, comprising subjects with T1D on MDI (n = 21), subjects with type 2 diabetes (T2D) on MDI (n = 59), and subjects with T1D on insulin pump therapy (n = 226).

Results: On an aggregated data set, the two-hour glucose prediction model, at a forecasting horizon of 30, 45, 60, and 120 minutes, achieved a percentage of data points in zones A and B of Consensus Error Grid of: 99.8%, 99.3%, 98.7%, and 96.3%, respectively. The 30-minute low glucose prediction model achieved an accuracy, sensitivity, specificity, mean lead time, and area under the receiver operating characteristic curve (ROC AUC) of: 98.9%, 95.2%, 98.9%, 16.2 minutes, and 0.958, respectively. The nighttime low glucose prediction model achieved an accuracy, sensitivity, specificity, and ROC AUC of: 86.5%, 55.3%, 91.6%, and 0.859, respectively.

Conclusions: The consistency of the performance of the three predictive models when evaluated on different cohorts of subjects with T1D and T2D on different insulin therapies, including real-world data, offers reassurance for real-world efficacy.

利用预测性应用程序增强连续葡萄糖监测功能
背景:尽管有大量证据表明连续血糖监测(CGM)对糖尿病管理大有裨益,但仍有相当一部分使用该技术的患者难以达到血糖目标。为了应对这一挑战,我们提出了 Accu-Chek® SmartGuide Predict 应用程序,它是一种创新的 CGM 数字伴侣,集成了一整套先进的血糖预测功能,旨在提前告知用户急性血糖状况:方法:该应用程序的功能由三个机器学习模型提供支持,包括两小时血糖预测、30 分钟低血糖检测和睡前低血糖预测。对模型性能的评估包括三个数据集,包括使用 MDI 的 T1D 受试者(n = 21)、使用 MDI 的 2 型糖尿病(T2D)受试者(n = 59)和使用胰岛素泵治疗的 T1D 受试者(n = 226):在综合数据集上,两小时血糖预测模型在 30 分钟、45 分钟、60 分钟和 120 分钟的预测范围内,共识误差网格 A 区和 B 区的数据点百分比分别为 99.8%、99.3% 和 99.3%:分别为 99.8%、99.3%、98.7% 和 96.3%。30 分钟低血糖预测模型的准确性、灵敏度、特异性、平均提前时间和接收器操作特征曲线下面积(ROC AUC)分别为:98.9%、95.2%和 96.3%:分别为 98.9%、95.2%、98.9%、16.2 分钟和 0.958。夜间低血糖预测模型的准确性、灵敏度、特异性和 ROC AUC 分别为:86.5%、55.3%、16.2 分钟和 0.958:结论:在对使用不同胰岛素疗法的 T1D 和 T2D 受试者组群(包括真实世界数据)进行评估时,这三种预测模型的性能保持一致,为真实世界的疗效提供了保证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Diabetes Science and Technology
Journal of Diabetes Science and Technology Medicine-Internal Medicine
CiteScore
7.50
自引率
12.00%
发文量
148
期刊介绍: The Journal of Diabetes Science and Technology (JDST) is a bi-monthly, peer-reviewed scientific journal published by the Diabetes Technology Society. JDST covers scientific and clinical aspects of diabetes technology including glucose monitoring, insulin and metabolic peptide delivery, the artificial pancreas, digital health, precision medicine, social media, cybersecurity, software for modeling, physiologic monitoring, technology for managing obesity, and diagnostic tests of glycation. The journal also covers the development and use of mobile applications and wireless communication, as well as bioengineered tools such as MEMS, new biomaterials, and nanotechnology to develop new sensors. Articles in JDST cover both basic research and clinical applications of technologies being developed to help people with diabetes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信